Drug Trial Radar · NCT02721186
Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22,500
Actual
Start
Apr 30, 2016
Primary completion
Dec 31, 2016
Study completion Sep 30, 2017
Sponsor
- Lead sponsor
- Ulrika MorrisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mahidol Oxford Tropical Medicine Research Unit; RTI International; The President's Malaria Initiative; University of California, San Francisco; Uppsala University; Zanzibar Malaria Elimination Programme
- First posted
- Mar 29, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria transmission in Shehias considered hotspots on Unguja Island, Zanzibar.
Conditions
- Malaria
- Plasmodium Infections
Interventions
MDA with DHAp and SLD PrimaquineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative notified malaria incidence in the MDA and control ShehiasTime frame: 6 months after second round of MDA
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zanzibar Malaria Elimination Programme
Mwanakwerekwe, Urban District, Zanzibar, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.